FDA announces that children aged 6 months through 4 years old who completed primary monovalent COVID-19 vaccination are now eligible to receive a bivalent booster dose, while agency advisers vote in favor of full Paxlovid approval.

To exclude 340B drugs from Medicare Part B inflation rebates required by the Inflation Reduction Act, providers must identify 340B drugs on Medicare claims. 

The guide tailors the 2018 National Institute of Standards and Technology Framework for Improving Critical Infrastructure Cybersecurity to the health sector.

Per the Inflation Reduction Act, drug manufacturers that increase prices faster than the inflation rate will be required to pay rebates to Medicare.

FDA announced March 10 that it will withdraw and revise several COVID-19 guidance documents, including emergency use authorization of surgical masks, as circumstances surrounding the virus evolve.

The updated guidance highlights the importance of sustaining a QAPI program over time and increasing engagement by the hospital’s governing body.

A bivalent vaccine that protects against SARS-CoV-2 and influenza will not be available this year, while a CDC advisory committee says there is not enough evidence to recommend more than one annual COVID-19 booster for immunocompromised people.

Two proposed rules would extend many flexible provisions enacted during the COVID-19 public health emergency for prescribing controlled substances.

Applications close May 31 for the two-year extension of the Bundled Payments for Care Improvement Advanced voluntary payment model.

FDA authorizes the first at-home nasal test that detects influenza A and B as well as COVID-19; Moderna reaches a $400 million agreement with the National Institutes of Health.

The order instructs agencies to produce an annual public equity action plan, build agency equity teams, and improve community engagement.

National Institutes of Health research finds that Black and Hispanic Americans face greater long COVID-19 risks, the CDC says that primary series vaccination protects children ages 3–5 for four months, and Novavax will deliver an additional 1.5 million doses.

The roadmap outlines which policies implemented under the COVID-19 public health emergency (PHE) will be affected when the PHE ends May 11.

Drug manufacturers that increase prices faster than the inflation rate must pay rebates to Medicare; comments on this policy are due to CMS March 11.

Following the agenda's release, HHS on Feb. 10 requested information on promising practices for advancing health equity for intersex individuals.

The updated fact sheets share when specific waivers will end and whether they will continue after the public health emergency's end on May 11.

Qualified individuals and their families who lose Medicaid or CHIP eligibility once the continuous enrollment requirement ends can apply for marketplace coverage between March 31, 2023, and July 31, 2024.

The Biden administration announced that the COVID-19 public health emergency, initially declared Jan. 27, 2020, will end May 11.

FDA's Vaccines and Related Biological Products Advisory Committee votes to replace the original monovalent COVID-19 vaccine, Evusheld no longer is authorized under emergency use, and the CDC launches a COVID-19 testing locator.

CMS reports that open enrollment through the health insurance marketplaces for 2023 totals 16.3 million people, a 13 percent increase from 2022.

An FDA committee will vote on the future of the COVID-19 vaccine, while CDC unveils two trackers for COVID-19, flu, and RSV–related hospital and emergency department visits.

The National Institutes of Health launches the Home Test to Treat program; FDA and CDC report a COVID-19 vaccine safety concern for those ages 65 and older.

America's Essential Hospitals and other plaintiffs had asked the judge to order an immediate repayment in full for five years of underpayments to 340B hospitals.

The association supports CMS' work to simplify enrollment and asks the agency to ensure equitable access to beneficiaries’ preferred health care providers.

Prioritizing hospitals in health professional shortage areas, CMS awarded residency slots to 100 hospitals, including 27 essential hospitals.